Evidence map›Paper›PMID 22949079›Full record

Trial reportEuropean journal of nuclear medicine and molecular imaging2012

¹⁸F-Fluoride PET/CT is highly effective for excluding bone metastases even in patients with equivocal bone scintigraphy.

Daniel C Bortot, Bárbara J Amorim, Glaucia C Oki, Sérgio B Gapski, Allan O Santos, Mariana C L Lima, Elba C S C Etchebehere, Marycel F Barboza, Jair Mengatti, Celso Dario Ramos

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. The performance ofScientific reports · 2026
    Article
  2. Article
  3. Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  4. Comparison ofWorld journal of nuclear medicine · 2022
    Review
  5. Comparison ofEuropean journal of hybrid imaging · 2022
    Article
  6. Article
  7. Letter to the Editor:European journal of nuclear medicine and molecular imaging · 2020
    Article
  8. Uptake of Radium-223 Dichloride and Early [Molecular imaging and biology · 2018
    Article
  9. Article
  10. Therapy assessment of bone metastatic disease in the era ofEuropean journal of nuclear medicine and molecular imaging · 2017
    Review
  11. Article
  12. Review
  13. Determination of Skeletal Tumor Burden on 18F-Fluoride PET/CT.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2015
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Daniel C BortotDivision of Nuclear Medicine, Department of Radiology, State University of Campinas, Avenue Zeferino Vaz, S/N., PO Box 6149, 13080-000 Campinas, Brazil.
Bárbara J Amorim
Glaucia C Oki
Sérgio B Gapski
Allan O Santos
Mariana C L Lima
Elba C S C Etchebehere
Marycel F Barboza
Jair Mengatti
Celso Dario Ramos

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBone scintigraphy (BS) has been used extensively for many years for the diagnosis of bone metastases despite its low specificity and significant rate of equivocal lesions. (18)F-Fluoride PET/CT has been proven to have a high sensitivity and specificity in the detection of malignant bone lesions, but its effectiveness in patients with inconclusive lesions on BS is not well documented. This study evaluated the ability of (18)F-fluoride PET/CT to exclude bone metastases in patients with various malignant primary tumours and nonspecific findings on BS.

methodsWe prospectively studied 42 patients (34-88 years of age, 26 women) with different types of tumour. All patients had BS performed for staging or restaging purposes but with inconclusive findings. All patients underwent (18)F-fluoride PET/CT. All abnormalities identified on BS images were visually compared with their appearance on the PET/CT images.

resultsAll the 96 inconclusive lesions found on BS images of the 42 patients were identified on PET/CT images. (18)F-Fluoride PET/CT correctly excluded bone metastases in 23 patients (68 lesions). Of 19 patients (28 lesions) classified by PET/CT as having metastases, 3 (5 lesions) were finally classified as free of bone metastases on follow-up. The sensitivity, specificity, and positive and negative predictive values of (18)F-fluoride PET/CT were, respectively, 100 %, 88 %, 84 % and 100 % for the identification of patients with metastases (patient analysis) and 100 %, 82 % and 100 % for the identification of metastatic lesions (lesion analysis).

conclusionThe factors that make BS inconclusive do not affect (18)F-fluoride PET/CT which shows a high sensitivity and negative predictive value for excluding bone metastases even in patients with inconclusive conventional BS.

Indexed as

Fluorodeoxyglucose F18Multimodal ImagingPositron-Emission TomographyRadiopharmaceuticalsTomography, X-Ray ComputedAdultAgedAged, 80 and overBone NeoplasmsFemaleHumansMaleMiddle AgedProspective StudiesFluorodeoxyglucose F18Radiopharmaceuticals

Identifiers

PMID22949079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.